Life Sciences

  • June 29, 2026

    Asthma Drug Developer To Wind Down In Chancery Court

    A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.

  • June 29, 2026

    Supreme Court Shuts Down 4 Patent Cases

    The U.S. Supreme Court turned down four petitions over patent law Monday, meaning it won't review questions related to prosecution laches, jury verdicts, patent eligibility and marking.

  • June 26, 2026

    4 Takeaways From The High Court's Monsanto Ruling

    The U.S. Supreme Court's highly anticipated ruling in favor of Monsanto over its blockbuster pesticide Roundup established that a pesticide's labeling must meet federal standards, ensuring that businesses don't have to comply with a variety of potentially conflicting state laws.

  • June 26, 2026

    PACER Fees Will Rise To Fund Cyber Defense Upgrades

    The federal judiciary announced Friday it will temporarily increase the fees for electronic access to court records to pay for a potential $800 million upgrade that will modernize and strengthen court records systems PACER and CM/ECF, an upgrade it previously said is needed to respond to escalating cyberattacks.

  • June 26, 2026

    Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit

    Pfizer defeated a former employee's whistleblower retaliation suit Friday after a California federal judge ruled the "uncontroverted material facts" show the company would have fired him for "legitimate, independent reasons" even if he did engage in protected whistleblowing.

  • June 26, 2026

    Endoscopy Device Maker's Trade Secret Suit Trimmed In Ohio

    An Ohio federal judge has kept alive most of medical equipment supplier Steris' lawsuit claim that a former research and development director stole its intellectual property to form a competitor, but agreed to trim some claims in the case.

  • June 26, 2026

    DC Circ. Affirms FDA Can Block Norwich's IBS Generic

    The D.C. Circuit on Friday backed the U.S. Food and Drug Administration's lower court win in Norwich Pharmaceuticals' challenge to the agency's refusal to approve an application to bring a generic version of a prescription antibiotic for irritable bowel syndrome to market until 2029.

  • June 26, 2026

    EU Probing Sanofi For Disparaging Rival Flu Vaccine

    European enforcers are investigating whether Sanofi used a messaging campaign directed mainly at healthcare professionals in Germany and France to disparage the only rival flu vaccine recommended for vulnerable patients.

  • June 26, 2026

    DEA Will Back Cannabis' Medical Utility In Historic Hearing

    The U.S. Drug Enforcement Administration will kick off three weeks of hearings Monday on a proposal to move marijuana from Schedule I to Schedule III under the Controlled Substances Act, by presenting testimony asserting that the drug has a valid, currently accepted medical use.

  • June 26, 2026

    ITC Votes To Tee Up Duties For Korean Chemical Imports

    The U.S. International Trade Commission found Friday certain monomers and oligomers imported from South Korea that were determined to be selling at less than fair value are harming domestic producers, teeing up duties to be ordered on those goods.

  • June 26, 2026

    Taxation With Representation: Sidley, Paul Weiss, Kirkland

    In this week's Taxation With Representation, Germany's Merck KGaA acquires life sciences tools supplier Bio-Techne Corp., drugmaker AbbVie buys clinical-stage biotechnology company Apogee Therapeutics, and building materials supplier CRH acquires infrastructure products maker Arcosa Inc.

  • June 26, 2026

    REIT Execs Hid Queens Megacampus Woes, Suit Says

    A stockholder for life sciences-focused real estate investment trust Alexandria Real Estate Equities Inc. has alleged in California federal court that the REIT's top executives lied about how much money the company was making from its leased Queens megacampus in New York.

  • June 26, 2026

    Don't Miss It: Sidley, Cooley Steer Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple of weeks, and it's difficult to keep up with all the deals. Here, Law360 recaps the ones you may have missed, including transactions helmed by Sidley Austin LLP and Cooley LLP.

  • June 25, 2026

    Sandoz Still Can't Escape Generics Claims From GM, Others

    A Pennsylvania federal judge on Thursday declined to rethink her decision forcing Sandoz's Swiss parent company to face generic-drug price-fixing claims from major employers like American Airlines Inc. and General Motors LLC, saying the pharmaceutical company "has no new evidence" backing up its argument that the court lacks personal jurisdiction.

  • June 25, 2026

    Robo-Surgery Co., FTC Urge 9th Circ. To Revive Antitrust Case

    Surgical Instrument Service and the Federal Trade Commission urged the Ninth Circuit on Thursday to revive the company's case accusing Intuitive Surgical of blocking third parties from refurbishing components for its da Vinci surgery robot, saying a lower court erred in requiring the U.S. Supreme Court's Kodak factors to be proven.

  • June 25, 2026

    Meta Fails To Knock Out BIPA Voiceprint Privacy Claims

    A California federal judge has refused to let Meta Platforms Inc. escape an Illinois woman's proposed class claims that Meta collects "voiceprints" in violation of Illinois' Biometric Information Privacy Act, saying in a ruling unsealed Thursday that whether Meta obtained her voice recordings in a way capable of identifying her was still up for dispute.

  • June 25, 2026

    Texas Faces Tough Questions In Tylenol Autism Appeal

    A Texas appellate court seemed skeptical Thursday of an argument that the parent entities of the company that sells Tylenol should have to defend claims that the pain reliever causes autism, suggesting that the companies don't have enough ties to Texas.

  • June 25, 2026

    Anti-Pot Advocates Preview Arguments In DEA Hearings

    The anti-cannabis parties participating in upcoming U.S. Drug Enforcement Administration hearings on a proposal to change marijuana's Schedule I status will argue that the drug poses too many public health and safety risks for the government to loosen restrictions on it.

  • June 25, 2026

    Novo Nordisk Gets 401(k) Investment Suit Narrowed

    A New Jersey federal judge dismissed allegations accusing Novo Nordisk of unlawfully keeping underperforming investment options in its employee 401(k) plan, handing the pharmaceutical company a partial win by concluding workers hadn't identified comparable funds that performed significantly better.

  • June 25, 2026

    No Immunity In Idaho THC Child Abuse Registry Suit

    An Idaho federal judge won't throw out a class action alleging Idaho violates constitutional rights by placing women on the state's Child Protection Central Registry for using THC during pregnancy, finding the director of the state's Department of Health and Welfare doesn't have immunity against the claims.

  • June 25, 2026

    Sidley Grows In Calif. With Life Sciences, Emerging Cos. Hires

    Sidley Austin LLP announced three partner hires in California, which the firm said will enhance its capabilities in the life sciences and emerging companies and venture capital practices.

  • June 25, 2026

    4th Circ. Says Supply Co.'s Foreign Member Kills Diversity

    The Fourth Circuit on Thursday declined to reinstate a medical supply company's contract dispute against a U.K. corporation over COVID-19 test kits, after finding that the lack of a U.S. citizen on the supply company's side destroys the court's diversity jurisdiction to hear the case.  

  • June 25, 2026

    2 Firms Lead Merck's $11.3B Bio-Techne Life Sciences Deal

    Germany's Merck has agreed to acquire Bio-Techne Corp. in an all-cash deal valuing the U.S.-based life sciences tools company at about $11.3 billion, including debt, the companies said Thursday.

  • June 25, 2026

    Monsanto Wins High Court Fight Over Roundup Cancer Warnings

    The U.S. Supreme Court on Thursday handed Monsanto a win in its long-running litigation battle over the labeling of alleged cancer risks of its bestselling weedkiller Roundup, clearing the path for a $7.25 billion settlement to end thousands of suits facing the Bayer AG unit by finding that the state law claims underlying a $1.25 million jury verdict are barred.

  • June 24, 2026

    NY Judge Halts DOJ Bid For Trans Youth Medical Records

    A New York federal judge Wednesday barred the U.S. Department of Justice from seeking medical records of transgender patients who received gender-affirming care as minors in the wake of a grand jury subpoena to NYU Langone Health System, saying the government's investigation doesn't outweigh the patients' privacy interests.

Expert Analysis

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.